The identification of bradykinin as the key mediator of symptoms of HAE, and demonstration of its production at the sites of swelling [2], [3] led to the clinical development of icatibant, a bradykinin B2 receptor antagonist, as a treatment option for HAE type I and II [4], [5]. The gene discussed is BDKRB2; the disease is hereditary angioedema.